Roche Takes Advantage Of COVID-19 Testing Rush
Executive Summary
Roche’s sales in 2020 increased by 1%, at constant exchange rates, to CHF 58.3bn, led by 14% growth in its diagnostics division.
You may also be interested in...
Diagnostics Saves Roche From Q1 Difficulties
In its first quarter 2021 sales earnings report, Roche highlighted the strength of its diagnostics business as biosimilars cannibalize its pharmaceutical revenues.
Roche Buys GenMark Diagnostics For $1.8Bn
GenMark’s syndromic panel testing portfolio complements Roche’s molecular diagnostics business.
FDA: Roche Test Flaws Could Misdiagnose Patients With COVID-19, Flu
The US agency has contacted health care providers to warn them about faulty COBAS SARS-CoV-2 and Influenza A/B Nucleic Acid Tests for use on the COBAS Liat System.